Monoclonal antibody therapeutics and risk for infection.
Gea-Banacloche
Juan C
JC
National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Weinberg
Geoffrey A
GA
D000074323:Alemtuzumab; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007165:Immunosuppression Therapy; D007239:Infections / Q000209:etiology*; D008214:Lymphocytes / Q000276:immunology / Q000502:physiology; D051379:Mice; D000069442:Natalizumab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000069442:Natalizumab; D014409:Tumor Necrosis Factor-alpha; D000074323:Alemtuzumab